Columvi (glofitamab-gxbm) Patient Assistance Program
Don’t let the high cost of brand CD20xCD3 bispecific antibody disrupt your relapsed/refractory large B-cell lymphoma treatment. We help eligible patients access Columvi (glofitamab-gxbm intravenous infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Columvi (glofitamab-gxbm) is FDA-approved for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy. (Indication expansion in combination with gemcitabine + oxaliplatin for second-line is under review.) CD20 × CD3 bispecific antibody with unique 2:1 CD20-binding format. Off-the-shelf alternative to CAR-T cell therapy with fixed treatment duration (12 cycles).
- Without assistance, Columvi costs commonly run approximately $13,000–$17,000 per dose (varies by cycle and step-up dosing schedule).
- Through AffordMyPrescriptions, qualifying patients can access Columvi for a flat $69.95 per month.
- Other relapsed/refractory DLBCL therapies: epcoritamab (Epkinly — competing CD20×CD3 bispecific, SC administration), CAR-T cell therapy (axicabtagene/Yescarta, lisocabtagene/Breyanzi, tisagenlecleucel/Kymriah — one-time cellular therapy at specialized centers), Polivy (polatuzumab vedotin) + bendamustine + rituximab (Pola-BR for 2L+ DLBCL), Loncastuximab tesirine (Zynlonta — CD19 ADC), tafasitamab (Monjuvi) + lenalidomide (Revlimid generic available), selinexor (Xpovio — XPO1 inhibitor), Lunsumio (mosunetuzumab — primarily FL but FL transformation to DLBCL covered). Standard salvage chemotherapy options (R-ICE, R-DHAP, R-GDP) with possible autologous SCT for transplant-eligible.
What is Columvi Prescription Assistance Program?
The Columvi Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Columvi (used for relapsed or refractory diffuse large B-cell lymphoma after at least two prior lines of systemic therapy) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, hematology/oncology coordination, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing aggressive lymphoma.
At AffordMyPrescriptions, our Patient Advocates handle the entire Columvi PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation, follow up with the manufacturer’s program until approval, manage your step-up dosing infusion schedule, and handle annual re-certification — so you never face a gap in your Columvi bispecific antibody therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Columvi enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your diffuse large B-cell lymphoma treatment.
Pharmacy Price Comparison
- Without assistance, Columvi costs thousands of dollars per dose at oncology centers. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted lymphoma therapy accessible if you qualify. The table below compares typical pricing across major settings to what you'd pay with our Columvi advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| CAR-T cell therapy (alt) | ~$425,000 total | Alt cellular therapy |
| Hospital oncology | ~$16,500/dose | Save substantially |
| Community oncology | ~$14,500/dose | Save substantially |
| Specialty pharmacy | ~$13,500/dose | Save substantially |
| 340B-eligible institution | ~$13,000/dose | Save substantially |
| Epkinly (alt bispecific) | ~$13,500/dose | Alt SC bispecific |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Columvi — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Columvi Prescription Program?
The Columvi Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Columvi offers off-the-shelf alternative to CAR-T with fixed treatment duration (12 cycles).
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Columvi assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Columvi is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Columvi:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $13,000–$17,000/dose per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Columvi assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Columvi Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Columvi:
Columvi is a CD20 × CD3 bispecific T-cell engager with unique 2:1 binding format (two anti-CD20 arms for higher tumor avidity, one anti-CD3 arm). The bispecific engagement brings T cells into proximity with CD20-expressing lymphoma cells, redirecting cytotoxic T-cell activity against tumor. Off-the-shelf alternative to CAR-T cell therapy. Pivotal trial established efficacy with durable responses in relapsed/refractory DLBCL.
How It Works:
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. Standard first-line R-CHOP cures approximately 60% of patients. Relapsed/refractory disease historically had limited effective options — autologous SCT, CAR-T cell therapy for chemorefractory patients, multiple targeted therapies emerging. Glofitamab has a 2:1 binding format — two CD20-binding arms (higher tumor avidity) and one CD3-binding arm — bringing T cells into proximity with CD20-expressing DLBCL cells, activating T cells, triggering cytotoxic T cell-mediated tumor cell killing. Step-up dosing in cycle 1 (with obinutuzumab pre-treatment to reduce CRS) mitigates cytokine release risk. Fixed treatment duration of 12 cycles.
Form and Use:
Columvi IV infusion. Single 1000 mg dose of obinutuzumab (anti-CD20) on cycle 1 day 1 to reduce CRS risk. Step-up dosing in cycle 1: day 8 (2.5 mg), day 15 (10 mg), day 22 (30 mg); cycles 2+ day 1 (30 mg every 21 days). Total 12 cycles. Premedication with corticosteroid, antihistamine, antipyretic. Monitor closely for CRS during initial cycles. CRS management with tocilizumab and corticosteroids. Periodic CBC, CMP. Tumor lysis syndrome prophylaxis (hydration, allopurinol).
Generic Availability:
No biosimilar/generic. Other CD20-targeting bispecific antibodies for B-cell lymphomas: epcoritamab (Epkinly — SC formulation for DLBCL and FL), mosunetuzumab (Lunsumio — primarily FL). Other relapsed/refractory DLBCL therapies: CAR-T cell therapy (axicabtagene ciloleucel/Yescarta per ZUMA-1, lisocabtagene maraleucel/Breyanzi per TRANSCEND NHL-001, tisagenlecleucel/Kymriah per JULIET — one-time cellular therapy with significant logistics), polatuzumab vedotin (Polivy) + bendamustine + rituximab biosimilars (Pola-BR per POLARIX for first-line and 2L+ trials), loncastuximab tesirine (Zynlonta — CD19 ADC), tafasitamab (Monjuvi) + lenalidomide (Revlimid — generic now), selinexor (Xpovio — XPO1 inhibitor). Standard salvage chemotherapy options (R-ICE, R-DHAP, R-GDP, R-MINE) with autologous SCT for transplant-eligible patients with chemosensitive disease. Allogeneic SCT for select cases. NCCN B-cell lymphoma guidelines guide selection.
Warnings:
Boxed warnings: cytokine release syndrome (CRS — common, especially with first doses; can be severe; obinutuzumab pretreatment and step-up dosing mitigate; manage with tocilizumab and corticosteroids), neurologic toxicity including immune effector cell-associated neurotoxicity syndrome (ICANS — monitor; manage with corticosteroids), serious infections (bacterial, viral, fungal — including hepatitis B reactivation; screen and consider HBV prophylaxis), tumor lysis syndrome (high disease burden — hydration, allopurinol). Other: cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), embryo-fetal toxicity, hypogammaglobulinemia (consider IVIG for recurrent infections), fatigue, pyrexia (often CRS-related). Live vaccines avoided.
FAQ (Frequently Asked Questions)
How much does Columvi cost without insurance?
$13,000–$17,000 per dose. Total 12-cycle treatment course can cost $200,000–$300,000. Specialty pharmacy and Patient Assistance Programs are essential. Time-limited treatment course distinguishes from indefinite-duration therapies.
Is Columvi considered chemotherapy?
No — Columvi is a targeted immunotherapy (bispecific T-cell engager antibody) — recruits the patient’s own T cells to kill tumor cells. Different mechanism from cytotoxic chemotherapy with different toxicity profile, including immunotherapy-specific toxicities like CRS and ICANS.
What is the difference between Columvi and Epkinly (epcoritamab)?
Both CD20×CD3 bispecific antibodies for relapsed/refractory DLBCL. Columvi (glofitamab) has unique 2:1 binding format (two CD20 arms), IV administration, 12-cycle fixed treatment course. Epkinly (epcoritamab) has 1:1 binding format, SC administration (convenient outpatient), indefinite-duration administration. Both effective; choice often by clinician preference, insurance, and patient logistics.
What is the difference between Columvi and CAR-T cell therapy?
Both target CD19 or CD20 on B-cell lymphoma using T cells. CAR-T (Yescarta, Breyanzi, Kymriah) requires harvesting patient T cells, genetic engineering, reinfusion — complex logistics, one-time infusion, ~$425,000+ cost, specialized centers, intensive monitoring. Columvi is off-the-shelf bispecific antibody, step-up dosing then every-3-week infusion, 12 cycles, treated at community oncology. Choice often by patient fitness, logistics, prior CAR-T eligibility, and clinician preference.
What is cytokine release syndrome (CRS) and how is it managed with Columvi?
CRS is immune activation with fever, hypotension, tachycardia, hypoxia — caused by T-cell activation releasing inflammatory cytokines. With Columvi, single-dose obinutuzumab pretreatment and step-up dosing in cycle 1 substantially mitigate CRS risk. Most CRS is grade 1–2; severe CRS treated with tocilizumab (anti-IL-6R) and corticosteroids. Close monitoring during initial cycles is essential.
Take Control of Your Medication Costs
Targeted bispecific antibody therapy for relapsed/refractory diffuse large B-cell lymphoma should not be derailed by cost. Columvi offers fixed 12-cycle treatment as off-the-shelf alternative to CAR-T. Our Columvi advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Columvi through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.